View Older Stories View More Recent Stories

Sep 14, 2020 07:00AM RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
Sep 14, 2020 06:12AM Regeneron (REGN) Reports Dupixent (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis
Sep 14, 2020 01:00AM FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
Sep 14, 2020 12:59AM FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
Sep 8, 2020 06:32AM Regeneron (REGN) SanoSNY) Reports New Results from Dupixent (dupilumab) Phase 3 Open-Label Extension Trial
Sep 8, 2020 01:00AM Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
Sep 8, 2020 12:59AM Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma
Sep 3, 2020 07:00AM Regeneron (REGN) Announces Late-breaking Libtayo Pivotal Data in Advanced NSCLC and Basal Cell Carcinoma to Be Presented at ESMO
Sep 3, 2020 07:00AM Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO
Sep 3, 2020 06:59AM Late-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO
Aug 26, 2020 07:00AM Regeneron Announces Investor Conference Presentations
Aug 19, 2020 05:02PM Regeneron (REGN) Announces NEJM Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Aug 19, 2020 05:01PM New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Aug 19, 2020 01:00AM Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19
Aug 12, 2020 07:01AM Regeneron (REGN) Announces FDA Accepts Evinacumab BLA for Priority Review as Treatment for Patients with HoFH
Aug 12, 2020 07:00AM FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Aug 5, 2020 06:30AM Regeneron Reports Second Quarter 2020 Financial and Operating Results
Jul 29, 2020 10:25PM Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas B
Jul 29, 2020 09:00PM Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas B
Jul 29, 2020 07:22AM Regeneron (REGN) Announces BARDA Procures its REGN-EB3 Investigational Ebola Treatment for National Preparedness
Jul 29, 2020 07:00AM BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness
Jul 8, 2020 04:30PM Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020
Jul 7, 2020 07:05AM Regeneron (REGN) Secures $450M Contract from BARDA/DoD to Manufacture and Supply REGN-COV2 Anti-Viral Antibody Cocktail
Jul 7, 2020 07:00AM Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
Jul 6, 2020 07:03AM Regeneron (REGN) Starts Phase 3 COVID-19 Trial of REGN-COV2
Jul 6, 2020 07:00AM Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
Jul 2, 2020 04:30PM Regeneron (REGN), Sanofi (SNY) Announce Kevzara Phase 3 U.S. Trial in COVID-19 Patients Did Not Meet its Primary and Secondary Endpoints
Jul 2, 2020 04:30PM Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Jul 2, 2020 04:29PM Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients
Jun 24, 2020 03:24PM Regeneron (REGN) Says There is No Merit to Civil Complaint, to Vigorously Defend Allegations Related to Contributions to Patient Assistance Charity
Jun 24, 2020 03:22PM Regeneron to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014
Jun 24, 2020 02:01PM Regeneron (REGN) Announces New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo
Jun 24, 2020 02:00PM New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab)
Jun 22, 2020 07:00AM Regeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation
Jun 19, 2020 01:51PM UPDATE: Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Dupixent (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
Jun 19, 2020 01:51PM FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
Jun 19, 2020 01:44PM FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
Jun 19, 2020 07:32AM Regeneron (REGN), Sanofi (SNY) announce Dupixent approved in China for adults with moderate-to-severe atopic dermatitis
Jun 19, 2020 07:32AM Regeneron (REGN), Sanofi (SNY) Confirm Dupixent (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Jun 19, 2020 07:30AM Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
Jun 19, 2020 07:30AM Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Jun 11, 2020 07:18AM Regeneron (REGN) Reports Two Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants
Jun 11, 2020 07:17AM Two Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants
Jun 11, 2020 07:04AM Regeneron (REGN) announced initiation of first clinical trial of REGN-COV2, dual antibody cocktail for prevention and treatment of COVID-19
Jun 11, 2020 07:00AM Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
Jun 11, 2020 12:59AM Regeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event
Jun 10, 2020 09:00AM Regeneron Recognized as Healthcare Sector Leader on "The Civic 50" List of the Most Community-Minded Companies in the United States
Jun 5, 2020 07:00AM Regeneron Announces Upcoming Investor Conference Presentations
Jun 1, 2020 07:04AM Regeneron (REGN) and Intellia Therapeutics (NTLA) Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Jun 1, 2020 07:00AM Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
View More Recent Stories View Older Stories